217 related articles for article (PubMed ID: 35108656)
1. Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study.
Wang H; Liu D; Wang C; Yu S; Jin G; Wang C; Zhang B; Zhang D; Shao D
Clin Res Hepatol Gastroenterol; 2022; 46(6):101869. PubMed ID: 35108656
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)-Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study.
Ouyang T; Cao Y; Chen L; Zheng C
Cardiovasc Intervent Radiol; 2022 Jun; 45(6):780-790. PubMed ID: 35410405
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma.
Li N; Yang P; Fang J
Clin Res Hepatol Gastroenterol; 2022 Nov; 46(9):102022. PubMed ID: 36089248
[TBL] [Abstract][Full Text] [Related]
4. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
[TBL] [Abstract][Full Text] [Related]
5. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma.
Chen S; Yu W; Zhang K; Liu W
BMC Cancer; 2018 Nov; 18(1):1131. PubMed ID: 30453925
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
Li N; Chen J
Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
[TBL] [Abstract][Full Text] [Related]
11. Apatinib plus drug-eluting bead transarterial chemoembolization as bridging therapy to surgical resection displays an acceptable efficacy and safety profile in hepatocellular carcinoma patients.
Yan J; Sun Y; Fan D; Mu W
Indian J Cancer; 2023 Oct; 60(4):562-569. PubMed ID: 36861729
[TBL] [Abstract][Full Text] [Related]
12. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
[TBL] [Abstract][Full Text] [Related]
13. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
14. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma.
Liu J; Xie S; Duan X; Chen J; Zhou X; Li Y; Li Z; Han X
Cancer Chemother Pharmacol; 2020 Jan; 85(1):69-76. PubMed ID: 31813003
[TBL] [Abstract][Full Text] [Related]
15. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
Yin L; Liu KC; Lv WF; Lu D; Tan YL; Wang GX; Dai JY; Zhu XH; Jiang B
Cancer Imaging; 2023 May; 23(1):52. PubMed ID: 37254146
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of transcatheter arterial chemoembolization combined with either
Li Y; Li H; Hu H; Yuan H; Zhao Y
J Cancer Res Ther; 2020; 16(7):1691-1697. PubMed ID: 33565518
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
18. Transarterial Chemoembolization plus Apatinib with or without Camrelizumab for the Treatment of Advanced HBV-related Hepatocellular Carcinoma.
Liu H; Yu Q; Gu T; Qu P; Ma X; Zhou S; Lu T; Pan D; Han Z
J Gastrointestin Liver Dis; 2023 Jun; 32(2):182-189. PubMed ID: 37345608
[TBL] [Abstract][Full Text] [Related]
19. The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Li D; Zhang C; Yang K; Ma Z; Ma L; Cheng C; Xu L; Wan S
Medicine (Baltimore); 2024 Jan; 103(3):e36865. PubMed ID: 38241568
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial.
Lu W; Jin XL; Yang C; Du P; Jiang FQ; Ma JP; Yang J; Xie P; Zhang Z
Cancer Biol Ther; 2017 Jun; 18(6):433-438. PubMed ID: 28548587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
